{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-392527","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2026-09-16T13:12:15+00:00","discovered_at":"2026-09-16T13:13:01.596939+00:00","generated_at":"2026-09-16T13:13:12.128820+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Alkermes appoints Anne C. Whitaker to board, expanding to 11 directors","bullets":["Board increased from 10 to 11 directors; Whitaker effective Sept. 14, 2026, term through 2027 AGM.","Whitaker receives $600,000 initial equity award (50% options, 50% RSUs), vesting in 3 annual installments.","She will receive standard annual cash retainer and equity grant per proxy statement director compensation.","CEO Blair Jackson cites Whitaker's commercial and operational expertise in neuroscience-focused pipeline.","Chairman Richard Pops welcomes Whitaker, citing her CEO and board experience across pharma/biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-392527","json":"https://secwatch.observer/filing/0001193125-26-392527.json","markdown":"https://secwatch.observer/filing/0001193125-26-392527.md","text":"https://secwatch.observer/filing/0001193125-26-392527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526392527/0001193125-26-392527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526392527/alks-20260914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T13:13:12.128820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"baa2f9c78c","claim":"Anne C. Whitaker was appointed as Director at Alkermes plc..","evidence_excerpt":"On September 14, 2026, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately, with an initial term expiring at the Company’s 2027 annual general meeting of shareholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526392527/0001193125-26-392527-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}